For clinicians
Sermorelin for prescribers: status, evidence and what FDA has said
A neutral reference. It reports Sermorelin's regulatory status, the quality of its human evidence and what FDA has said about it. It does not suggest a dose, a protocol or a source.
Status reviewed 2026-10-01 · By the Grey Peptides Editorial Board · Regulatory fields generated from our tracker
| Also known as | — |
| FDA approval | Not FDA-approved |
| Compounding (503A) | Not compoundable (nomination withdrawn; on no FDA list) |
| Outsourcing (503B) | No 503B status recorded |
| WADA 2026 List | Prohibited (S2.2.4) |
| WADA 2027 List | Prohibited (S2.2.4) |
| Evidence grade | Medium |
| Status reviewed | 2026-10-01 |
What FDA has said
FDA has not placed Sermorelin on its list of bulk substances that may present significant safety risks (current as of 2026-04-22), and this page has no other FDA review of it to report.
Monitoring: what the literature does and does not say
- No label. Sermorelin has no FDA-approved label, and therefore no labelled guidance on monitoring.
- Not on FDA's safety-risks list. Sermorelin does not appear on FDA's list of bulk substances that may present significant safety risks (current as of 2026-04-22). That is an absence of a listing, not a finding of safety.
These are gaps, not a monitoring schedule. This page does not supply one, and for a compound in this position the human evidence would not support one.
Compounding: where it stands
Today's position for Sermorelin: Not compoundable (nomination withdrawn; on no FDA list). An FDA advisory committee's vote is a non-binding recommendation; until FDA acts, a vote does not change what may be compounded. Our explainer on the 503A and 503B categories sets out what each status means, and the regulatory tracker is updated as FDA acts.
The evidence
A 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of growth hormone-releasing hormone, formerly marketed as Geref for pediatric GH deficiency and as a diagnostic agent.
The encyclopedia entry lists the human and animal studies we hold, each with its PMID.
What this page leaves out
Doses, regimens, cycle lengths and sources. That is deliberate. A reference that reports status and evidence is useful only if it is not also a protocol, and for a compound in this position there is no approved one to report.
Sources
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 2026-04-22; read 2026-10-01. FDA
- Grey Peptides regulatory tracker, row for Sermorelin, reviewed 2026-10-01. Tracker · dataset
- World Anti-Doping Agency. Prohibited List 2027, dated August 26, 2026, in force January 1, 2027. WADA
This page is a reference for qualified professionals. It is not medical advice, it does not recommend any treatment, and it is not a substitute for the prescriber's own judgement and their state and federal obligations.
Others in this group: AOD-9604 · Cathelicidin (LL-37) · Cerebrolysin · CJC-1295 · Dihexa · GHK-Cu (injectable) · GHRP-6 · Hexarelin · Ipamorelin · Melanotan II · MK-677 (ibutamoren) · Noopept · PEG-MGF · Pralmorelin (GHRP-2) · Selank · Tesofensine · Thymopentin · Thymosin α-1